2012;3:811C823. cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, medication cytotoxicity was elevated, indicating that autophagy is normally a protective system. Therefore, our results claim that PI3K/Akt/mTOR inhibitors protect lymphocyte viability. That is a valuable lead to be taken into consideration when selecting medications for targeted cancers therapy to be able to minimize harmful effects on immune system function. and than p110 or skillet PI3K course I inhibitors [24]. Organic killer cell-mediated cytotoxicity aswell as antibody reliant mobile cytotoxicity against tumor cells had been considerably impaired by skillet course I PI3K inhibitors, whereas p110 selective medications had no impact [51, 57]. Various other authors show recently that one inhibitors of course I PI3K isoforms in T-lymphocytes exerted a much less powerful impairment of T-cell activation than simultaneous inhibition of several isoforms [54]. These outcomes suggest that comprehensive blockade of course I PI3K activity highly impairs T lymphocyte proliferation and activation and and in vivo. Clin Cancers Res. 2011;17:7116C7126. [PubMed] [Google Scholar] 31. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 works well in multiple myeloma highly. Anti-cancer medications. 2012;23:131C138. [PubMed] [Google Scholar] 32. Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both hypoxic and normoxic hepatocarcinoma cells. Oncotarget. 2015;6:17147C17160. doi:?10.18632/oncotarget.3940. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 33. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, et al. Cytotoxic activity of the book Akt inhibitor, MK-2206, in T-cell severe lymphoblastic leukemia. Leukemia. 2012;26:2336C2342. [PubMed] [Google Scholar] 34. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The Akt inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells exhibiting hyperphosphorylated synergizes and Akt-1 with conventional chemotherapy. Oncotarget. 2013;4:1496C1506. doi:?10.18632/oncotarget.1236. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 35. Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Triple Akt inhibition as a fresh healing technique in T-cell severe lymphoblastic leukemia. Oncotarget. 2015;6:6597C6610. doi:?10.18632/oncotarget.3260. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 36. Wang Y, Liu J, Qiu Y, Jin M, Chen X, Enthusiast G, Wang R, Kong D. ZSTK474, a particular course I phosphatidylinositol 3-kinase inhibitor, induces G1 autophagy and arrest in human breasts cancer MCF-7 cells. Oncotarget. 2016 doi:?10.18632/oncotarget.7658. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 37. Tasian SK, Teachey DT, Rheingold SR. Concentrating on the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Frontiers in oncology. 2014;4:108. [PMC free of charge content] [PubMed] [Google Scholar] 38. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, et al. Efficiency from the investigational mTOR kinase inhibitor MLN0128/Printer ink128 in types of B-cell severe lymphoblastic leukemia. Leukemia. 2013;27:586C594. [PMC free of charge content] [PubMed] [Google Scholar] 39. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation being a potential healing target for different illnesses. Nat Rev Medication Discov. 2012;11:709C730. [PMC free of charge content] [PubMed] [Google Scholar] 40. Gewirtz DA. The autophagic response to rays: relevance for rays sensitization in cancers therapy. Radiation analysis. 2014;182:363C367. [PubMed] [Google Scholar] 41. Klionsky DJ. Stepping back again from the rules: Where perform we stand? Autophagy. 2016;12:223C224. [PMC free of charge content] [PubMed] [Google Scholar] 42. Kampa-Schittenhelm Kilometres, Heinrich MC, Akmut F, Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. Cell cycle-dependent activity of the book dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in severe leukemia. Mol Cancers. 2013;12:46. [PMC free of charge content] [PubMed] [Google Scholar] 43. Simioni C, Cani A, Martelli AM, Zauli G, Tabellini.Cell cycle-dependent activity of the book dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. as leukemic cell lines shown a cell routine stop, caspase-dependent apoptosis, and dephosphorylation of essential the different parts of the signaling pathway. Autophagy was also induced in proliferating lymphocytes and in JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, medication cytotoxicity was elevated, indicating that autophagy is normally a protective system. Therefore, our results claim that PI3K/Akt/mTOR inhibitors protect lymphocyte viability. That is a valuable lead to be taken into consideration when selecting medications for targeted cancers therapy to be able to minimize harmful effects on immune system function. and than p110 or skillet PI3K course I inhibitors [24]. Organic killer cell-mediated cytotoxicity aswell as antibody reliant mobile cytotoxicity against tumor cells had been considerably impaired by skillet course I PI3K inhibitors, whereas p110 selective medications had no impact [51, 57]. Various other authors show recently that one inhibitors of course I PI3K isoforms in T-lymphocytes exerted a much less powerful impairment of T-cell activation than simultaneous inhibition of several isoforms [54]. These outcomes suggest that comprehensive blockade of course I PI3K activity highly impairs T lymphocyte proliferation and activation and and in vivo. Clin Cancers Res. 2011;17:7116C7126. [PubMed] [Google Scholar] 31. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous concentrating on of PI3K and mTOR with NVP-BGT226 is normally impressive in multiple myeloma. Anti-cancer medications. 2012;23:131C138. [PubMed] [Google Scholar] 32. Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 shows cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 2015;6:17147C17160. doi:?10.18632/oncotarget.3940. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 33. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, et al. Cytotoxic activity of the book Akt inhibitor, MK-2206, in T-cell severe lymphoblastic leukemia. Leukemia. 2012;26:2336C2342. [PubMed] [Google Scholar] 34. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The Akt inhibitor MK-2206 is normally cytotoxic in hepatocarcinoma cells exhibiting hyperphosphorylated Akt-1 and synergizes with typical chemotherapy. Oncotarget. 2013;4:1496C1506. doi:?10.18632/oncotarget.1236. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 35. Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Triple Akt inhibition as a fresh healing technique in T-cell severe lymphoblastic leukemia. Oncotarget. 2015;6:6597C6610. doi:?10.18632/oncotarget.3260. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 36. Wang Y, Liu J, Qiu Y, Jin M, Chen X, Enthusiast G, Wang R, Kong D. ZSTK474, a particular course I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in individual breast cancer tumor MCF-7 cells. Oncotarget. 2016 doi:?10.18632/oncotarget.7658. [PMC free of charge content] [PubMed] [CrossRef] [Google Scholar] 37. Tasian SK, Teachey DT, Rheingold SR. Concentrating on the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Frontiers in oncology. 2014;4:108. [PMC free of charge content] [PubMed] [Google Scholar] 38. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, et al. Efficiency from the investigational mTOR kinase inhibitor MLN0128/Printer ink128 in types of B-cell severe lymphoblastic leukemia. Leukemia. 2013;27:586C594. [PMC free of charge content] [PubMed] [Google Scholar] 39. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation being a potential healing target for different illnesses. Nat Rev Medication Discov. 2012;11:709C730. [PMC free of charge content] [PubMed] [Google Scholar] 40. Gewirtz DA. The autophagic response to rays: relevance for rays sensitization in cancers therapy. Radiation analysis. 2014;182:363C367. [PubMed] [Google Scholar] 41. Klionsky DJ. Stepping back again from the rules: Where perform we stand? Autophagy. 2016;12:223C224. [PMC free of charge content] [PubMed] [Google Scholar] 42. Kampa-Schittenhelm Kilometres, Heinrich MC, Akmut F, Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. Cell cycle-dependent activity of the book dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in severe leukemia. Mol Cancers. 2013;12:46. [PMC free article] [PubMed] [Google Scholar] 43. Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey.Nat Rev Malignancy. lines displayed a cell cycle block, caspase-dependent apoptosis, and dephosphorylation of important components of the signaling pathway. Autophagy was also induced in proliferating lymphocytes and in JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, drug cytotoxicity was increased, indicating that autophagy is usually a protective mechanism. Therefore, our findings suggest that PI3K/Akt/mTOR inhibitors preserve lymphocyte viability. This is a valuable result to be taken into account when selecting drugs for targeted malignancy therapy in order to minimize detrimental effects on immune function. and than p110 or pan PI3K class I inhibitors [24]. Natural killer cell-mediated cytotoxicity as well as antibody dependent cellular cytotoxicity against tumor cells were significantly impaired by pan class I PI3K inhibitors, whereas p110 selective drugs had no effect [51, 57]. Other authors have shown recently that single inhibitors of class I PI3K isoforms in T-lymphocytes exerted a less potent impairment of T-cell activation than simultaneous inhibition of two or more isoforms [54]. These results suggest that total blockade of class I PI3K activity strongly impairs T lymphocyte proliferation and activation and and in vivo. Clin Malignancy Res. 2011;17:7116C7126. [PubMed] [Google Scholar] 31. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is usually highly effective in multiple myeloma. Anti-cancer drugs. 2012;23:131C138. [PubMed] [Google Scholar] 32. Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 2015;6:17147C17160. doi:?10.18632/oncotarget.3940. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 33. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012;26:2336C2342. [PubMed] [Google Scholar] 34. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The Akt inhibitor MK-2206 is usually cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated Akt-1 and synergizes with standard chemotherapy. Oncotarget. 2013;4:1496C1506. doi:?10.18632/oncotarget.1236. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 35. Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget. 2015;6:6597C6610. doi:?10.18632/oncotarget.3260. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 36. Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, Wang R, Kong D. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast malignancy MCF-7 cells. Oncotarget. 2016 doi:?10.18632/oncotarget.7658. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 37. Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Frontiers in oncology. 2014;4:108. [PMC free article] [PubMed] [Google Scholar] 38. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27:586C594. [PMC free article] [PubMed] [Google Scholar] 39. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11:709C730. [PMC free article] [PubMed] [Google Scholar] 40. Gewirtz DA. The autophagic response to radiation: relevance for radiation sensitization in malignancy therapy. Radiation research. 2014;182:363C367. [PubMed] [Google Scholar] 41. Klionsky DJ. Stepping back from the guidelines: Where do we stand? Autophagy. 2016;12:223C224. [PMC free article] [PubMed] [Google Scholar] 42. Betamethasone acibutate Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Malignancy. 2013;12:46. [PMC free article] [PubMed] [Google Scholar] 43. Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its.Gewirtz DA. by the drugs whereas mitogen-stimulated lymphocytes as well as leukemic cell lines displayed a cell cycle block, caspase-dependent apoptosis, and dephosphorylation of key components of the signaling pathway. Autophagy was also induced in proliferating lymphocytes and in JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, drug cytotoxicity was increased, indicating that autophagy is usually a protective mechanism. Therefore, our findings suggest that PI3K/Akt/mTOR inhibitors preserve lymphocyte viability. This is a valuable result to be taken into account when selecting drugs for targeted malignancy therapy in order to minimize detrimental effects on immune function. and than p110 or pan PI3K class I inhibitors [24]. Natural killer cell-mediated cytotoxicity as well as antibody dependent cellular cytotoxicity against tumor cells were significantly impaired by pan class I PI3K inhibitors, whereas p110 selective drugs had no effect [51, 57]. Other authors have shown recently that single inhibitors of class I PI3K isoforms in T-lymphocytes exerted a less potent impairment of T-cell activation than simultaneous inhibition of two or more isoforms [54]. These results suggest that total blockade of class I PI3K activity strongly impairs T lymphocyte proliferation and activation and and in vivo. Clin Malignancy Res. 2011;17:7116C7126. [PubMed] [Google Scholar] 31. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is usually highly effective in multiple myeloma. Anti-cancer drugs. 2012;23:131C138. [PubMed] [Google Scholar] 32. Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 2015;6:17147C17160. doi:?10.18632/oncotarget.3940. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 33. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012;26:2336C2342. [PubMed] [Google Scholar] 34. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The Akt inhibitor MK-2206 is usually cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated Akt-1 and synergizes with standard chemotherapy. Oncotarget. 2013;4:1496C1506. doi:?10.18632/oncotarget.1236. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 35. Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget. 2015;6:6597C6610. doi:?10.18632/oncotarget.3260. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 36. Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, Wang R, Kong D. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget. 2016 doi:?10.18632/oncotarget.7658. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 37. Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Frontiers in oncology. 2014;4:108. [PMC free article] [PubMed] [Google Scholar] 38. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27:586C594. [PMC free article] [PubMed] [Google Scholar] 39. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11:709C730. [PMC free article] [PubMed] [Google Scholar] 40. Gewirtz DA. The autophagic response to radiation: relevance for radiation sensitization in cancer therapy. Radiation research. 2014;182:363C367. [PubMed] [Google Scholar] 41. Klionsky DJ. Stepping back from the guidelines: Where do we stand? Autophagy. 2016;12:223C224. [PMC free article] [PubMed] [Google Scholar] 42. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer. 2013;12:46. [PMC free article] [PubMed] [Google Scholar] 43. Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget. 2014;5:10034C10047. doi:?10.18632/oncotarget.2490. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 44. Mu Q, Ma Q, Lu S, Zhang T, Yu M, Huang X, Chen J, Jin J. 10058-F4, a.Leukemia. of autophagy were analyzed by Western blotting. Quiescent healthy T lymphocytes were unaffected by the drugs whereas mitogen-stimulated lymphocytes as well as leukemic cell lines displayed a cell cycle block, caspase-dependent apoptosis, and dephosphorylation of key components of the signaling pathway. Autophagy was also induced in proliferating lymphocytes and in JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, drug cytotoxicity was increased, indicating that autophagy is a protective Betamethasone acibutate mechanism. Therefore, our findings suggest that PI3K/Akt/mTOR inhibitors preserve lymphocyte viability. This is a valuable result to be taken into account when selecting drugs for targeted cancer therapy in order to minimize detrimental effects on immune function. and than Betamethasone acibutate p110 or pan PI3K class I inhibitors [24]. Natural killer cell-mediated cytotoxicity as well as antibody dependent cellular cytotoxicity against tumor cells were significantly impaired by pan class I PI3K inhibitors, whereas p110 selective drugs had no effect [51, 57]. Other authors have shown recently that single inhibitors of class I PI3K isoforms in T-lymphocytes exerted a less potent impairment of T-cell activation than simultaneous inhibition of two or more isoforms [54]. These results suggest that complete blockade of class I PI3K activity strongly impairs T Rabbit Polyclonal to OR10G4 lymphocyte proliferation and activation and and in vivo. Clin Cancer Res. 2011;17:7116C7126. [PubMed] [Google Scholar] 31. Baumann P, Schneider L, Mandl-Weber S, Oduncu F, Schmidmaier R. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anti-cancer drugs. 2012;23:131C138. [PubMed] [Google Scholar] 32. Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 2015;6:17147C17160. doi:?10.18632/oncotarget.3940. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 33. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012;26:2336C2342. [PubMed] [Google Scholar] 34. Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The Akt inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated Akt-1 and synergizes with conventional chemotherapy. Oncotarget. 2013;4:1496C1506. doi:?10.18632/oncotarget.1236. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 35. Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget. 2015;6:6597C6610. doi:?10.18632/oncotarget.3260. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 36. Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, Wang R, Kong D. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 Betamethasone acibutate cells. Oncotarget. 2016 doi:?10.18632/oncotarget.7658. [PMC free article] [PubMed] [CrossRef] [Google Scholar] 37. Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Frontiers in oncology. 2014;4:108. [PMC free article] [PubMed] [Google Scholar] 38. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27:586C594. [PMC free article] [PubMed] [Google Scholar] 39. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11:709C730. [PMC free article] [PubMed] [Google Scholar] 40. Gewirtz DA. The autophagic response to radiation: relevance for radiation sensitization in cancer therapy. Radiation research. 2014;182:363C367. [PubMed] [Google Scholar] 41. Klionsky DJ. Stepping back from the guidelines: Where do we stand? Autophagy. 2016;12:223C224. [PMC free article] [PubMed] [Google Scholar] 42. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer. 2013;12:46. [PMC free article] [PubMed] [Google Scholar] 43. Simioni C, Cani A,.
2012;3:811C823
